Muscle Relaxant Drugs Market

Muscle Relaxant Drugs Market: Global Industry Analysis and Opportunity Assessment 2017-2027

  • Ongoing
  • September 2020
  • REP-GB-2836
  • Format: PDF/PPT/Excel
  • SELECT LICENSE TYPE :

  • US$5,000
  • US$7,500
  • US$10,000

This Muscle Relaxant Drugs market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Muscle Relaxant Drugs market.

Muscle relaxant drugs are primarily used in conjunction with general anesthetics to achieve muscle relaxation during surgical interventions. However, they are also being used in the treatment of muscle spasm and spastic neurological conditions secondary to multiple sclerosis, cerebral palsy, fibromyalgia, myofascial pain syndrome etc. Muscle relaxants can be used in alleviating acute pain in muscle spasm, tension headache etc. Spasticity arises from conditions affecting brain and spinal cord, and lasts for a long time. However, muscle relaxant drugs only provide symptomatic treatment and do not cure the underlying disease or disorder. Loss of muscle tone associated with old age, due to loss of fibrous tissue and reduced vascular network in the skin makes old age population the biggest target group for the use of skeletal muscle relaxant drugs. Moreover, geriatric population is highly prone to the musculoskeletal disorders including Carpal Tunnel syndrome, ligament sprain etc. Muscle relaxant drugs are commercially being used from 1940s, and since 1995, 10 new muscle relaxant drugs have been introduced in a market including vecuronium, Atracurium etc. Some of the commonly used brands of skeletal muscle relaxant drugs include Gablofen (baclofen injection), Lioresal Intrathecal (baclofen), Soma (Carisoprodol), Lorzone (Chlorzoxazone), Flexeril (Cyclobenzaprine), Dantrium (Dantrolene),  Skelaxin  (Metaxalone) and others. According to the Medicaid reported data, carisoprodol, cyclobenzaprine and metaxalone comprised 45% of overall prescription for lower back pain in the U.S. in 2015.

  • Identify Key Market Forces and their Long-Term Forecast
  • Sneak Peek into Key Forecast Factors and thier Impact

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

Muscle Relaxant Drugs Market: Drivers and Restraints

Global market for muscle relaxant drugs is primarily driven by increasing incidence of lower back pain, surge in number of surgical procedures and expanding geriatric population. Low back pain has been ranked among the top 5 causes of physician visits in the U.S. In 2007, The American Pain Society and the American College of Physicians published a guideline for the treatment of low back pain in which skeletal muscle relaxants are recommended as a second line therapy for low back pain. Moreover, changing prescription practices may alter the growth rate of muscle relaxant drugs market. For instance, even though muscle relaxants drugs are not recommended as a first line of therapy 35% of patients suffering from non-specific lower back pain are prescribed with muscle relaxants in the U.S. However, severe side effects related to muscle relaxant drugs such as habituation and respiratory arrest will restrict the growth of global muscle relaxant drugs market.

Muscle Relaxant Drugs Market: Overview

The global market for muscle relaxant drugs is expected to gain traction during the forecast period due to increasing aging population and availability of generic drugs. Centrally acting muscle relaxant drugs segment is expected to hold the largest share in the global muscle relaxant drugs market due to increasing number of prescriptions. However, facial aesthetic relaxants segment is expected to witness highest growth rate due to increasing number of facial and cosmetic surgeries and changing perception of beauty all over the world. Increasing usage of neuromuscular blocking agents during general surgeries would drive the growth of global market for muscle relaxant drugs

Muscle Relaxant Drugs Market: Regional Wise Outlook

Geographically, the global muscle relaxant drugs market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America will continue to hold largest share in the global muscle relaxant drugs market due to rising number of ANDA applications being filed by the key players. Europe is expected to hold second largest share in global market for muscle relaxant drugs market. However, APAC is expected to witness highest growth rate due to expansion activities by the key players in the regionand launch of generic muscle relaxant drug formulations.

Muscle Relaxant Drugs Market: Key Players

Some of the market players operating in global muscle relaxant drugs market are Abbott Laboratories, Mallinckrodt plc., Medtronic Neuromodulation (Medtronic Inc.), Vertical Pharmaceuticals LLC, Johnson & Johnson, Par Sterile Products, LLC., Endo Pharmaceuticals, Inc., SteriMax Inc. and others. Companies are facing patent cliff as majority of the muscle relaxant drugs have lost the patent exclusivity. However, generic players such as Upsher Smith Laboratories, Inc., Orient Pharma Co., Ltd. and others are introducing generic versions of these drugs in the global muscle relaxant drugs market.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, Rest Of MEA)

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Muscle Relaxant Drugs Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Muscle Relaxant Drugs Market: Segmentation

The global muscle relaxant drugs market has been segmented on the basis of product type, formulation, retail sales channel, and geography.

Based on product type, the global muscle relaxant drugs market is divided into following:

  • Peripherally Acting Muscle Relaxants
  • Neuromuscular Blocking Agents (e.g. Tubocurarine,
  • Direct Acting Muscle Relaxants (e.g. Dandroline, )
  • Facial Aesthetic Relaxants (e.g. Botulinum toxin A)
  • Centrally Acting Muscle Relaxants (e.g. Carisoprodol, Chlorzoxazone etc.)

Based on formulation, the global muscle relaxant drugs market is divided into following:

  • Solid Oral Formulations
  • Injectable Formulations

Based on retail sales channels, the global muscle relaxant drugs market is segmented as below:

  • Hospital Pharmacy
  • Online sales
  • Retail Pharmacy
  • Drug Stores

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Muscle Relaxant Drugs Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Muscle Relaxant Drugs Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch

Harish Tiwari

Global Head - Business Development

Akshay Godge

Client Partner - Global Business Development

Our Clients


Request Sample Request customization Request Methodology